CRT 2025

Panel Discussion | Atherosclerosis Therapeutic Options and Management - What is Promising?

Panel Moderator(s)

• 

  Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI

  Professor of Cardiology and Population Health Science and Policy, Mount Sinai Endowed Professor in Cardiovascular Clinical Research and Outcomes; Director of Interventional Cardiovascular Research and Clinical Trials; Director of Women’s Heart and Vascular Center at Mount Sinai Heart
  Icahn School of Medicine at Mount Sinai, New York
  New York, New York, United States

  Disclosure(s): Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere Medical, Medtronic, Novartis, Protembis GmbH, Sanofi, RM Glo: Grant/Research Support (Ongoing); AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program): Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Elixir Medical, Stel, ControlRad (spouse): Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Elixir Medical, IQVIA, Medtronic, Medscape/WebMD Global, NovoNordisk: Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing); SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director): SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director) (Ongoing)
• 

  Charles German, MD, MS, FAHA, FASPC

  Assistant Professor
  Georgetown University

  Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

• 

  C. Michael Gibson, MD

  Professor of Medicine
  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure information not submitted.
• 

  Paul A. Gurbel, MD, FSCAI

  Director
  Sinai Center for Thrombosis Research and Drug Development
  Baltimore, Maryland, United States

  Disclosure information not submitted.
• 

  Elvin Kedhi, MD

  Interventional Cardiologist Head of Innovation
  Universite libre de Bruxelles
  Westmount/ Montreal, Quebec, Canada

  Disclosure information not submitted.
• 

  Ramzi Khamis, MD PhD

  Consultant Cardiologist. Clinical Director of Cardiology and Cardiothoracic Surgery
  Imperial College London and Imperial College Healthcare NHS Trust
  London , England, United Kingdom

  Disclosure information not submitted.
• 

  Michael Mahmoudi, MD

  Honorary Professor of Interventional Cardiology
  University Hospital Southampton NHS FT
  Southampton, England, United Kingdom

  Disclosure(s): No financial relationships to disclose
• 

  Nehal N. Mehta, MD, MSCE

  Clinical Professor of Medicine
  The George Washington University
  Washington, District of Columbia, United States

  Disclosure information not submitted.
• 

  Robert S. Rosenson, MD

  Director of Metabolism and Lipids
  Mount Sinai Health System
  New York, New York, United States

  Disclosure(s): Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Avilar Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Editas Medicine: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing); GSK: Consulting Fees (e.g., advisory boards) (Ongoing); Intercept Pharmaceuticals Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Kowa American Corporation: Non-promotional lecture (Ongoing); Life Extension: Consulting Fees (e.g., advisory boards) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); MediMergent LLC: Stock-privately held company (Ongoing); New Amsterdam: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Organon: Consulting Fees (e.g., advisory boards) (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Rona Therapeutics, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve: Consulting Fees (e.g., advisory boards) (Ongoing); Viatris: Non-promotional lecture (Ongoing); William Blair: Consulting Fees (e.g., advisory boards) (Ongoing); Wolters Kluwer: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
• 

  Scott W. Shurmur, MD

  Chair, Internal Medicine; Interventional PD
  Texas Tech Health Sciences Center, Lubbock
  Lubbock, Texas, United States

  Disclosure(s): No financial relationships to disclose
• 

  Jean-Claude Tardif, MD

  Director of Research Center
  Montreal Heart Institute
  Montreal, Quebec, Canada

  Disclosure(s): Boehringer Ingelheim Pharmaceutical, Inc.: Grant/Research Support (Ongoing); Ceapro: Grant/Research Support (Ongoing); DalCor Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Merck Pharmaceuticals: Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Grant/Research Support (Ongoing); Pfizer,: Grant/Research Support (Ongoing); Verve Therapeutics: Grant/Research Support (Ongoing)
• 

  Allen J. Taylor, MD

  Chairman of Cardiology
  MedStar Heart and Vascular Institute
  Washington, District of Columbia, United States

  Disclosure(s): Amgen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Heartflow, Inc: Consultant (Ongoing)